Home » CBD Regulation in Europe: Nine Countries, Nine Rulebooks — and Almost Nobody Trained to Use It
CBD regulation in Europe

CBD Regulation in Europe: Nine Countries, Nine Rulebooks — and Almost Nobody Trained to Use It

Walk into a pharmacy in Zagreb and you can buy CBD oil off the shelf. Cross into Italy and the same bottle may fall under narcotics law. Fly to Helsinki and it might legally be a medicine you cannot import without a prescription. Same molecule, same plant, same European Union — three completely different answers. A new review has finally put all of those answers side by side, and the picture it produces is less a single market than a patchwork stitched together in the dark.

The analysis was published in the Journal of Clinical Medicine in August 2026 by a team from the University of Split and the Split-Dalmatia County pharmacy service, led by Ana Batinic and Davorka Sutlovic. The authors compared how CBD is regulated and actually used in Croatia against six other European countries plus Canada and Australia, pulling from PubMed, Scopus and Web of Science alongside official documents from the EMA, EFSA, the European Commission and national medicines agencies. Their conclusion is blunt: the shopping aisle has raced far ahead of the clinic, almost everywhere.

Key Takeaways

CBD is now easy to buy in most of Europe and still hard to prescribe. Across Croatia, Germany, the Netherlands, Slovenia, Italy, France and Finland, the review found wildly different legal classifications for the same products — food, cosmetic, medicine, or controlled substance depending on which border you are standing behind. Germany and the Netherlands have built working medical cannabis systems with pharmacists at the centre; Finland treats most CBD as a medicine by default and keeps the market small; Italy tightened its rules sharply in 2025. Croatia sits in the middle: shelves full of CBD, clinics that barely use it, and more than 80% of surveyed doctors and pharmacists saying they want proper training before they do. Only one purified CBD medicine, Epidyolex, holds EU marketing authorisation, and only for rare, severe epilepsy syndromes and tuberous sclerosis. Everything else on the shelf is a consumer product that has never been assessed to pharmaceutical standards. This was a narrative review of laws and practice, not a trial — it tells you how the rules differ, not whether CBD works.

The 0.3% Line That Decides Everything

Hemp and marijuana are the same species. Botanically there is no distinction at all; Cannabis sativa L. is Cannabis sativa L. The split is legal, not biological, and it usually falls at 0.3% THC by dry weight. Below that line a plant is an agricultural crop. Above it, it is a controlled drug.

THC is the compound that gets people high, acting on receptors that are packed into the brain and that help govern mood, memory, appetite and pain. CBD barely touches those same receptors, which is why it does not intoxicate — and why regulators have spent a decade arguing about what box to put it in (for the full science, see CBD explained). The plant makes more than 150 related compounds beyond these two, most of them barely studied.

That ambiguity is the root of the whole mess. A CBD product can plausibly be classified as a medicine, a food, a cosmetic, a tobacco product or a narcotic, and different governments have picked different boxes. More than 1,200 studies involving CBD are now registered on ClinicalTrials.gov, and the evidence points to a broad range of possible effects — anti-seizure, anti-anxiety, anti-inflammatory, antioxidant, pain-related. But the review is careful here: convincing clinical evidence exists for only a small handful of uses, and our recent coverage of what happened when scientists screened nearly 4,000 studies on CBD and neurological disease found much the same thing. Wide interest, narrow proof.

Germany and the Netherlands: How It Looks When a System Actually Works

Germany comes out of this comparison looking like the most complete model in Europe. Medical cannabis has been legal there since 2017. In April 2024 the Cannabis Act moved medical and scientific cannabis out of narcotics law entirely and into its own framework, while separately allowing adults to carry 25 grams in public, keep 50 at home, and grow up to three plants.

What matters clinically is not the home-grow allowance but the machinery underneath it. German doctors can prescribe cannabis flower, extracts and pharmacy-compounded preparations for serious illness when standard treatment has not worked — chronic pain, multiple sclerosis spasticity, chemotherapy nausea, some drug-resistant epilepsies. Statutory health insurance can cover it after prior approval. Pharmacists compound the preparations to national quality standards, check the prescriptions, counsel patients and monitor side effects. Consumer CBD oils and cosmetics sit in a completely separate lane, and CBD foods and supplements are not authorised at all, because the safety assessment for them remains suspended for lack of data.

The Netherlands built something similar by a different route. A government office licenses producers, buys their entire output, and distributes standardised products to pharmacies — five of them, ranging from a THC-heavy variety at around 22% to a CBD-dominant one with almost no THC. That central control means a patient gets the same composition every time, which is exactly what medical use requires. The catch is money: Dutch patients often pay for treatment themselves, whereas eligible Germans can have it reimbursed. And on the consumer side the Dutch are unexpectedly strict, tolerating CBD products only up to 0.05% THC — among the tightest thresholds in Europe.

The Restrictive End: Finland, Italy and the Reversal Nobody Expected

Finland runs the strictest model in the review. Its medicines agency generally treats CBD preparations as medicinal products and assesses them case by case, which means importing CBD without a prescription can be illegal depending on what is in the bottle and where it came from. Herbal medical cannabis requires a special permit. Pharmacy compounding of cannabinoid preparations is not routine. The upside, as the authors note fairly, is that poorly characterised products largely stay out of the country. The downside is that patients who might benefit wait longer, or never get access at all.

Italy is the surprise. It has a mature, well-run medical cannabis system — authorised medicines, state-supervised production, pharmacy compounding — and in 2025 it went the other way on consumer products. Decree-Law No. 48/2025 pulled industrial hemp flowers under narcotics regulation regardless of how little THC they contain, and oral CBD is now essentially restricted to prescription pharmaceutical use. Legal scholars have already flagged the obvious problem: in 2020 the EU’s top court ruled that member states cannot simply block CBD lawfully produced in another member state unless there is a genuine, proportionate public health reason. Italy’s new rules will be tested against that.

France: A Booming Shop Window With a Locked Clinic Door

France is the mirror image of Italy. Its consumer market is one of the largest in Europe — oils, cosmetics, e-liquids, capsules, sweets and flowers have been widely sold since around 2015, and a national survey found roughly one adult in ten has tried CBD. Yet clinical access to cannabinoid medicines remains narrow, limited to a few authorised products for specific conditions under medical supervision.

France also produced the legal moment that reshaped the continent. The Kanavape case ended with the Court of Justice ruling that CBD lawfully extracted from the whole plant is not a narcotic under the 1961 UN convention, provided it has no psychotropic effect. When France later tried to ban CBD-rich flowers and leaves, the Conseil d’État suspended the measure as disproportionate given the actual scientific evidence on risk. That has not stopped the tinkering, as our report on the French ban on CBD edibles while smokable products stayed legal showed — the format, not the molecule, keeps deciding legality.

Croatia: Shelves Full, Guidance Empty

Croatia is the case study the review was built around, and it is a familiar story compressed into one country. CBD oils, capsules and cosmetics are sold through pharmacies, specialist shops and online. Epidyolex is the only authorised CBD medicine, and public reimbursement is tightly drawn: patients aged two and over with Lennox-Gastaut syndrome, Dravet syndrome in combination with clobazam, or tuberous sclerosis complex whose seizures persist despite at least two appropriate anti-epileptic drugs. Treatment must be approved by a hospital medicines committee on an epilepsy specialist’s recommendation, and continued coverage depends on documented response. Medicines containing dronabinol, THC or nabilone can be prescribed by GPs, but only after a specialist recommends it.

The gap is in the middle. Croatian surveys of doctors, pharmacists and health students found broadly positive attitudes toward CBD alongside substantial knowledge gaps about what it does, how safe it is and what its legal status even is — with more than 80% asking for further education. Community pharmacists, the professionals customers actually talk to when buying an unregulated oil, have the least formal role of any country reviewed. Regulatory uncertainty, thin clinical guidance and lingering stigma from CBD’s association with recreational cannabis complete the picture. Croatian researchers have contributed real clinical data of their own, including trials of CBD in patients with high blood pressure, but the authors are clear that more controlled studies are needed.

Legal Does Not Mean Implemented: Lessons From Canada and Australia

Canada legalised medical and non-medical cannabis in 2018 and built a national system for production, distribution and prescribing, complete with clinical guidance for practitioners. Yet even there, pharmacist compounding of cannabis preparations is restricted and outright prohibited in some provinces — the opposite of the German, Dutch and Slovenian model. Reimbursement varies province by province.

Australia offers the sharpest illustration of the gap between a law and a reality. It opened a regulatory pathway in 2021 for low-dose CBD to be sold by pharmacists without a prescription. Five years on, no product has been approved for that route. Most medicinal cannabis products in Australia remain unregistered and reach patients through special access schemes, with Epidyolex the main product carrying public subsidy. A pathway that exists on paper and delivers nothing in practice is a problem European regulators should recognise, because several are building the same thing.

The Two-Milligram Question Nobody Talks About in the Shop

One number in the review deserves more attention than it gets. Europe’s food safety authority has proposed a provisional safe intake level for CBD of about 0.0275 mg per kilogram of body weight per day — roughly 2 mg daily for a 70-kilogram adult. Many consumer oils on sale across Europe suggest doses many times that figure.

That number is provisional, not a verdict, and it reflects unresolved uncertainty rather than proven harm. But it is the reason CBD foods and supplements remain unauthorised across the EU: since 2018, 194 novel food applications have been submitted to the European Commission, and the safety assessment has stalled for want of adequate data. CBD cosmetics are a separate matter and can be sold if they meet EU cosmetics rules. The practical consequence for a shopper is uncomfortable — the product in your hand may be legal to sell and simultaneously unassessed for the dose printed on the label.

What This Review Can and Cannot Tell You

Honesty about the method matters here. This was a narrative review, not a systematic one. There was no PRISMA flow diagram, no formal risk-of-bias assessment and no meta-analysis. The authors selected sources for relevance rather than applying fixed inclusion criteria, and they say so plainly.

It also has a shelf life. Regulatory information was reviewed up to 3 August 2026, and this is a field where a single decree can invert a market in a week — as Italy demonstrated. Only nine jurisdictions were examined, so the findings describe those systems rather than Europe as a whole; anyone wanting the broader map can consult our country-by-country guide to cannabis law across Europe. And crucially, this paper is about rules and practice, not efficacy. It does not tell you whether CBD helps your condition. It tells you that if it did, whether you could get it, who would supervise it, and who would pay depends almost entirely on which passport you hold.

FAQ

Is CBD legal across the European Union?

There is no single EU answer. Cosmetics containing CBD can generally be sold if they comply with EU cosmetics rules, but CBD in foods and supplements requires novel food authorisation that has not yet been granted anywhere in the bloc. Beyond that, classification is national: France permits a broad consumer market, the Netherlands tolerates products only up to 0.05% THC, Italy has pulled hemp flowers under narcotics law, and Finland treats most CBD preparations as medicines requiring a prescription.

Why is Epidyolex the only CBD medicine I keep hearing about?

Because it is the only purified CBD product with EU-wide marketing authorisation, and it was approved for narrow indications: specific severe childhood epilepsy syndromes and tuberous sclerosis. A separate authorised product, nabiximols, combines THC and CBD for multiple sclerosis spasticity. Everything else sold as CBD is a consumer product that has not passed the same evidence, quality and safety review.

If a shop CBD oil is sold legally, does that mean it has been checked for safety?

Not in the way a medicine has. The review stresses that consumer CBD products are not evaluated to the pharmaceutical standards applied to authorised medicines, and that quality, labelling accuracy and contamination remain live concerns. The authors call for traceable supply chains, certificates of analysis and routine testing for pesticides, heavy metals and additives — which implies those things are not yet standard.

In Croatia specifically, can my GP prescribe cannabis-based treatment?

Partly. Croatian rules allow general practitioners to prescribe medicines containing dronabinol, THC or nabilone for selected conditions such as multiple sclerosis, cancer-related symptoms, treatment-resistant epilepsy and HIV/AIDS, but only following a recommendation from an authorised specialist such as a neurologist or oncologist. Reimbursement for Epidyolex through the national health insurance fund is restricted to defined epilepsy and tuberous sclerosis criteria and requires hospital committee approval.

Disclaimer

This article is journalism about published scientific and regulatory literature, not medical or legal advice. It does not recommend the use of any cannabis or CBD product and should not be used to guide treatment decisions. Cannabinoids can interact with prescription medicines; anyone considering their use should speak with a qualified doctor or pharmacist. Laws governing cannabis and CBD differ substantially between countries and change frequently — verify the current rules in your own jurisdiction before acting on anything described here.

You may also like